Investor Presentation Released: FY26 Operating Revenue Crosses USD 1Bn, PAT Growth 33.1%
Emcure has released its September 2026 Investor Presentation to the exchanges.
- Operating Revenue FY26
- USD 1Bn+
- Revenue Growth FY26
- +16.6%
- PAT Growth FY26
- 33.1%
- PAT Growth Margin Expansion
- 120 bps YoY
What was shared
Emcure Pharmaceuticals informed BSE and NSE under Regulation 30 of the SEBI LODR Regulations that it has released its Investor Presentation dated September 2026. The same document is available on the company's website. This is a disclosure of information, not a corporate action — no transaction, approval or order is involved.
Headline figures on the cover slide
- Operating Revenue FY26: USD 1Bn+
- Revenue growth FY26: +16.6%
- PAT Growth (FY26): 33.1%, shown with ▲120 bps YoY
What the presentation covers
- Company Overview — described as a diversified pharma company with scale in India and differentiated international businesses
- India Business — described as a scaled, chronic-led domestic franchise
- International Business — Europe, Canada and Rest of World
- Research & Development — differentiated R&D platforms
- Manufacturing — compliant, complex manufacturing scale
- Sustainability, and Governance & Leadership
- Appendix with financials for FY26 and Q1 FY27
How investors usually read this
An investor presentation is management's own structured summary of performance, business mix and strategy. The growth figures on the cover are the numbers the company has chosen to lead with, and the theme "Complex Science. Disciplined Execution. Compounding Value." signals the narrative it wants investors to follow.
A point of caution
The deck carries a standard disclaimer noting that statements about strategy, expansion plans, R&D pipeline, regulatory developments and future performance are forward-looking and subject to risks such as regulatory changes, competitive pressures, supply chain challenges, currency fluctuations and product commercialisation timelines. Such statements are expectations, not commitments, and the company states it undertakes no obligation to update them.
Also from Emcure Pharmaceuticals
Orders imposing Rs. 57,73,96,732 aggregate penalty received from Income-tax Department
2 Oct 2026
More numbers
- Revenue growth FY26+16.6%
- PAT Growth FY2633.1%
- YoY change shown with PAT growth▲120 bps YoY
- Operating Revenue FY26USD 1Bn+
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.